MedTrace Logo

Naltrexone in Treatment of Cocaine Dependence - 5

NCT00015080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of naltrexone in the treatment of cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2) decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in treatment.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Naltrexone

Sponsors & Collaborators

  • Cincinnati MDRU

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Eugene Somoza, M.D., Ph.D. · Cincinnati MDRU

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-05-31
Primary Completion
1996-06-30
Completion
1996-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00015080 on ClinicalTrials.gov